Injuries & Orthopedics
Best Peptides for Muscle Growth: Evidence & WADA (2026)
An evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.
FollistatinCJC-1295 with DACIpamorelinMGF / PEG-MGFIGF-1 LR3
The quick verdict
Ranked by strength of evidence for muscle growth specifically — and the honest verdict is that no candidate reaches Grade A: the whole category tops out at follistatin gene therapy in muscle disease plus GH-secretagogue biomarker trials, with the most-hyped agents carrying the weakest human evidence and the largest safety liabilities.
- Best overall
- Follistatin (FS-344) — gene therapy only — The only candidate with direct human muscle-tissue hypertrophy data — increased fiber diameter and walking distance — but exclusively via AAV gene therapy in muscle disease (Grade B). The injectable 'Follistatin-344' peptide sold online has no human trial and is Grade D.
- Best value
- Resistance training + protein + sleep (non-peptide baseline) — The interventions with actual Grade A human evidence for building muscle are progressive resistance training, adequate protein and sleep — free, upstream of every peptide here, and the benchmark any peptide should be measured against. That is what the evidence actually supports.
- Best for Human RCT data of any kind
- CJC-1295 with DAC — CJC-1295 has the strongest human RCT anchor in the class — Phase 1 trials proving GH rose 2-10x and IGF-1 1.5-3x — but it is a biomarker result only; no completed trial ever measured muscle, so lean-mass claims remain Grade C/D.
How we evaluated
We ranked each peptide strictly by the strength of published evidence for muscle growth or lean mass specifically — not by marketing volume or popularity. We separated human data from animal and in-vitro data, weighted actual muscle-outcome data (measured mass, fiber size, strength or function) above biomarker or expression data, distinguished the injectable peptide product from any gene-therapy or recombinant analog it borrows credibility from, and graded honestly where the only support is preclinical, mechanistic or anecdotal. No candidate reaches a Grade A human muscle-outcome trial; the highest grade reached for this condition is B.
- On-target human muscle-outcome evidence. Controlled or open-label human trials that measured actual muscle mass, fiber size, strength or function — not a biomarker. Only follistatin (via gene therapy in muscle disease) has any direct human muscle-tissue data; none reaches a healthy-adult RCT.
- Human biomarker / mechanism evidence. Human trials proving the intended hormonal effect (GH and IGF-1 rise, or MGF expression). CJC-1295 and ipamorelin have Phase 1 biomarker RCTs; MGF has human expression data — all short of a muscle outcome.
- Product-versus-analog honesty. Whether the marketed injectable peptide is what was actually studied, or whether its reputation is borrowed from a gene-therapy construct (follistatin) or recombinant/pegylated analog (MGF) that behaves differently.
- Mechanistic plausibility. Whether the proposed mechanism (GH/IGF-1 axis drive, myostatin-brake removal, local IGF-1 splice signaling) plausibly translates into functional muscle in a healthy adult, given negative-feedback limits and receptor questions.
- Safety and legal status. Condition-specific risks (hypoglycemia, organ overgrowth, pro-tumor signaling, glucose dysregulation), FDA compounding status, and WADA prohibition as of June 2026.
Rating scale: 1-5 stars reflecting strength of evidence FOR muscle growth specifically (5 = controlled human muscle-outcome proof; 3 = direct human muscle data in disease or strong human biomarker data; 1 = no human data). No peptide here exceeds 3.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Follistatin (FS-344) | B | 3.0 | Readers researching the only peptide with direct human muscle-hypertrophy data — understanding it comes from gene therapy in disease, not the injectable product | Not FDA-approved; injectable sold as research chemical / gene therapy investigational only |
| 2 | CJC-1295 with DAC | B | 2.5 | Readers who want the candidate with the best human RCT data — recognizing those trials proved hormonal effect only, never muscle growth | Not FDA-approved; PCAC rejected compounding; sold as research chemical |
| 3 | Ipamorelin | B | 2.0 | Readers comparing the selective GH-secretagogue half of the popular stack — understanding its one efficacy trial failed and no muscle trial exists | Not FDA-approved; not on permitted 503A bulks list; sold as research chemical |
| 4 | MGF / Mechano-Growth Factor (IGF-1Ec) | C | 1.5 | Readers evaluating the 'post-workout repair signal' claim — understanding the human data are expression studies and the injectable rationale is unproven | Not FDA-approved; sold as research chemical |
| 5 | IGF-1 LR3 | C | 1.0 | Readers who have seen aggressive IGF-1 LR3 marketing and want an honest, evidence-first accounting of why it is the highest-risk, weakest-evidence option here | Not FDA-approved (only native mecasermin is approved, a different molecule); sold as research chemical |
Follistatin (FS-344)
The only candidate with direct human muscle hypertrophy data — but only via gene therapy in disease
Follistatin is an endogenous ligand trap that binds and neutralizes myostatin and activin A, removing the chief catabolic brake on skeletal-muscle growth and disinhibiting satellite-cell activity upstream of the ActRIIB receptor. It is the only peptide in this review with direct human evidence of muscle hypertrophy — but that evidence comes from AAV gene therapy, not the injectable peptide. Two small open-label trials delivering AAV1.CMV.FS344 by intramuscular quadriceps injection (n=6 each) showed real muscle-tissue change: in Becker muscular dystrophy, increased fiber diameter (roughly 40 to 59 micrometers), reduced fibrosis, and improved 6-minute-walk distance in most subjects; in sporadic inclusion body myositis, annualized walk distance improved by +56 metres per year in treated patients versus -25.8 in untreated (P=0.01). These are open-label, n=6, localized viral-vector studies in muscle disease — Grade B, not an RCT and not in healthy adults. Animal data are spectacular and consistent (transgenic follistatin overexpression raised muscle mass 194 to 327 percent), but none of this validates the injectable 'Follistatin-344' peptide sold online, which has a ~1 to 2 hour half-life utterly unlike sustained gene-therapy expression and no human muscle-building trial. That use is Grade D. Honest grade: B for the gene therapy in disease, D for the peptide product.
Strengths
- The only candidate with direct human muscle-tissue hypertrophy data — increased fiber diameter and walking distance in two open-label gene-therapy trials
- Mechanistically the most upstream lever in the class: neutralizes myostatin and activin A to remove the growth brake rather than pushing the GH/IGF-1 accelerator
- Animal data are unusually large and consistent — transgenic overexpression raised muscle mass 194-327% and a single gene injection sustained gains for over two years
- The gene-therapy trials reported no serious adverse events and no disruption of reproductive hormones over their short, localized follow-up
Weaknesses
- All direct human muscle data is from AAV gene therapy in muscle disease, n=6, open-label — not the injectable peptide and not healthy adults (the peptide is Grade D)
- Native follistatin protein has a ~1-2 hour half-life, so a subcutaneous bolus is pharmacokinetically nothing like sustained gene-therapy expression, undermining the injectable rationale
- Trapping activin A removes a pro-apoptotic brake and carries a documented pro-angiogenic/pro-tumor signaling concern; rapid hypertrophy can also outpace tendon/ligament adaptation
- Prohibited by WADA at all times under S4.3 (myostatin-binding proteins named explicitly), plus M3 gene doping for the AAV construct; not FDA-approved
- Best for
- Readers researching the only peptide with direct human muscle-hypertrophy data — understanding it comes from gene therapy in disease, not the injectable product
- Pricing
- Not FDA-approved; injectable sold as research chemical / gene therapy investigational only
Source: Mendell et al., Mol Ther 2015 (follistatin gene therapy, PMC4426808)
CJC-1295 with DAC
The strongest human RCT anchor in the class — but the outcome measured was a biomarker, not muscle
CJC-1295 with DAC is a long-acting GHRH-receptor agonist engineered to bind covalently to albumin, giving it a multi-day half-life (roughly 6 to 8 days) and letting it push the body to release its own growth hormone on a sustained schedule. It has the strongest human randomized-trial anchor of any candidate here: two randomized, double-blind, placebo-controlled Phase 1 ascending-dose trials in healthy adults showed it raises GH 2 to 10-fold for at least six days and IGF-1 1.5 to 3-fold for nine to eleven days, cumulatively elevated up to 28 days on repeat dosing. The decisive limitation is that this is a biomarker and pharmacokinetic result, not a muscle-outcome result — development was halted at Phase 2, and no completed trial has ever measured lean mass, hypertrophy or strength from CJC-1295. Lean-mass claims are therefore Grade C/D, extrapolated from recombinant-GH literature rather than demonstrated for this peptide. The DAC version also produces a sustained, non-pulsatile 'GH bleed' rather than physiologic pulses, carrying class risks of fluid retention, arthralgia, carpal-tunnel symptoms and insulin resistance. Honest grade: B for the biomarker RCT, C/D for muscle.
Strengths
- The strongest human RCT anchor in the class — two placebo-controlled Phase 1 trials proving robust, prolonged GH and IGF-1 elevation in healthy adults
- Long albumin-bound half-life (~6-8 days) permits weekly dosing and sustained axis stimulation, the clearest pharmacology of any candidate here
- GHRH-receptor mechanism drives the body's own GH rather than injecting the effector directly, so IGF-1 negative feedback provides some ceiling on excess
Weaknesses
- No completed trial ever measured muscle, lean mass or strength — every muscle claim is Grade C/D extrapolation from recombinant-GH data, not demonstrated for this peptide
- Clinical development was terminated at Phase 2 (after a participant death attributed to pre-existing coronary disease), so chronic safety was never characterized
- Sustained non-pulsatile 'GH bleed' carries class risks: fluid retention, arthralgia, carpal-tunnel symptoms, insulin resistance and a theoretical IGF-1-driven neoplasia concern
- Not FDA-approved; PCAC voted against compounding eligibility (Dec 2024); WADA-prohibited at all times under S2.2.4 and detectable for 28+ days
- Best for
- Readers who want the candidate with the best human RCT data — recognizing those trials proved hormonal effect only, never muscle growth
- Pricing
- Not FDA-approved; PCAC rejected compounding; sold as research chemical
Source: Teichman et al., JCEM 2006 (Phase 1 RCT, PMID 16352683)
Ipamorelin
Reliably releases GH in humans — but its only efficacy RCT failed and no muscle trial exists
Ipamorelin is a selective ghrelin/GHS-R1a agonist whose standout property is clean selectivity: it reliably and dose-proportionally releases growth hormone in humans (Phase 1 pharmacokinetics show a peak around 40 minutes and a half-life of about 2 hours) without meaningfully raising ACTH, cortisol or prolactin, unlike the older GHRP-2 and GHRP-6. That selective GH pulse is the whole reason it is paired with CJC-1295 in popular stacks. But the honest limitation is decisive: ipamorelin's only published efficacy randomized trial — a Phase 2 study in postoperative ileus, roughly 114 patients — failed its primary endpoint, and the program was discontinued for lack of efficacy. No human RCT has ever tested ipamorelin for muscle, lean mass or body composition, so those claims are Grade C at best (animal body-weight and bone-growth data) and Grade D as marketed for physique. It sits one rank below CJC-1295 because, while both have human biomarker data, ipamorelin's single hard efficacy endpoint was negative. Honest grade: B for the human GH-release data, C/D for muscle.
Strengths
- Reliably and dose-proportionally releases GH in humans with a clean selectivity profile — minimal effect on cortisol, ACTH or prolactin versus older GHRPs
- Well-characterized human Phase 1 pharmacokinetics (peak ~40 min, t1/2 ~2 h) and good short-term tolerability in controlled trials
- Rodent data show body-weight gain and bone growth consistent with GH/IGF-1 axis activation, providing a coherent mechanistic rationale
Weaknesses
- Its only published efficacy RCT (postoperative ileus, n~114) failed its primary endpoint and the program was discontinued for lack of efficacy
- No human RCT has ever measured muscle, lean mass or body composition — physique claims are Grade C (animal) to D (anecdotal)
- No peer-reviewed subcutaneous pharmacokinetics for the community dosing routes; chronic SC use is unstudied
- Not FDA-approved and not on the permitted 503A bulks list as of mid-2026; WADA-prohibited at all times under S2.2.4
- Best for
- Readers comparing the selective GH-secretagogue half of the popular stack — understanding its one efficacy trial failed and no muscle trial exists
- Pricing
- Not FDA-approved; not on permitted 503A bulks list; sold as research chemical
Source: Beck et al., Int J Colorectal Dis 2014 (Phase 2 RCT, negative, PMID 25331030)
MGF / Mechano-Growth Factor (IGF-1Ec)
Human data are expression studies, not intervention — and the injectable rationale is mechanistically shaky
MGF (mechano-growth factor, the IGF-1Ec splice variant) is produced locally in muscle after damaging exercise; its E-peptide is thought to kick-start satellite-cell proliferation in an early, distinct phase of repair — notably through a still-unidentified receptor that is not the IGF-1 receptor. The human evidence is observational expression data, not intervention: MGF messenger RNA rises sharply after high-resistance exercise, but a controlled human study found the increase only in young men (25 to 36 years) and not in elderly men (70 to 82), suggesting age-related desensitization to mechanical loading. In cell culture the MGF 24-amino-acid E-peptide increased the proliferative lifespan of muscle progenitor cells from young but not old donors. Crucially, no human interventional trial of injected MGF or PEG-MGF exists, so for the injectable peptide product the muscle-building claim is Grade D. Animal PEG-MGF (pegylated to extend the half-life from minutes to about 24 hours) produced measurable hypertrophy after intramuscular injection in mice — the basis of the 'kick-starts repair' narrative — but a review argues MGF may act largely as an intracellular peptide, and in growth-plate cells exogenous MGF failed to stimulate proliferation, casting doubt on how an injected extracellular peptide would even work. Honest grade: C for the animal/expression biology, D for the injectable product.
Strengths
- Genuine human expression data — MGF mRNA rises after high-resistance exercise, giving the molecule a real physiological role in early muscle repair
- Animal PEG-MGF produced measurable intramuscular hypertrophy in mice, supporting the 'kick-starts satellite-cell repair' mechanistic story
- Mechanistically distinct from the GH/IGF-1 accelerators — a local, mechano-sensitive splice variant acting in an early repair phase
Weaknesses
- No human interventional trial of injected MGF or PEG-MGF exists — the human data are expression/biopsy studies only, so the injectable product is Grade D
- The E-peptide effect is not mediated by the IGF-1 receptor, and a review argues MGF may act intracellularly, casting doubt on how an injected extracellular peptide would work
- The exercise-induced expression response occurs in young but not elderly muscle, and exogenous MGF failed to stimulate proliferation in some assays
- No human safety data for injected MGF; sold as a research chemical with identity/purity risk; WADA-prohibited at all times under S2
- Best for
- Readers evaluating the 'post-workout repair signal' claim — understanding the human data are expression studies and the injectable rationale is unproven
- Pricing
- Not FDA-approved; sold as research chemical
Source: Hameed et al., J Physiol 2003 (MGF expression, PMID 12562960)
IGF-1 LR3
The most-hyped, highest-risk, weakest-evidence option — zero human trials and a lethal animal signal
IGF-1 LR3 (Long R3 IGF-1) is an engineered analog designed to evade the IGF-binding proteins that normally sequester about 99 percent of circulating IGF-1, prolonging IGF-1-receptor activation and delivering the anabolic effector directly rather than driving the body's own GH. It is heavily marketed for muscle and recovery, but the evidence is the weakest and the risk the highest in this review. There are zero published human clinical trials of IGF-1 LR3 for any indication, so bodybuilding claims are Grade D — anecdotal and mechanistic only. In animals it is roughly 1.5 to 2-fold more potent than native IGF-1 for body-weight and organ gain, but that potency cuts the wrong way: it drives disproportionate visceral organ growth rather than balanced muscle, and in the most rigorous recent study (growth-restricted fetal sheep) it failed to improve body weight and caused four fetal demises — all in LR3-treated animals — with roughly 42 percent glucose drops and 30 percent PaO2 drops, prompting a safety halt to dose-escalation. Hypoglycemia is the dominant acute hazard because LR3 weakly binds the insulin receptor, and chronically high IGF-1 carries an epidemiology-anchored cancer concern. Honest grade: C for the animal biology, D for humans — highest risk in the class.
Strengths
- Delivers the anabolic effector (IGF-1 signaling) directly and, by evading binding proteins, sustains IGF-1-receptor activation longer than native IGF-1
- Roughly 1.5-2x more potent than native IGF-1 for body-weight and organ gain in rodent models
- Mechanistically the most 'direct' anabolic lever — which is precisely why it is so aggressively marketed despite the absence of human data
Weaknesses
- Zero published human clinical trials for any indication — every muscle/recovery claim is Grade D anecdote or mechanism, not demonstrated benefit
- In the most rigorous animal study it failed to grow tissue and caused four fetal demises (all LR3-treated) from hypoglycemia/hypoxemia; dose-escalation was halted for safety
- Hypoglycemia is the dominant acute hazard (LR3 weakly binds the insulin receptor); it drives disproportionate visceral organ overgrowth rather than balanced muscle
- Chronically elevated IGF-1 is associated with increased cancer risk in large human epidemiology; black-market product tests as oxidized/degraded/His-tagged; WADA-prohibited at all times under S2
- Best for
- Readers who have seen aggressive IGF-1 LR3 marketing and want an honest, evidence-first accounting of why it is the highest-risk, weakest-evidence option here
- Pricing
- Not FDA-approved (only native mecasermin is approved, a different molecule); sold as research chemical
Source: White et al., Am J Physiol Endocrinol Metab 2024 (LR3 fetal-sheep failure, PMC11901354)
Frequently asked
Which peptide has the best evidence for actually building muscle?
For direct human muscle hypertrophy, follistatin — but only via AAV gene therapy in muscle disease, not the injectable peptide sold online. Two small open-label trials of AAV1.CMV.FS344 in Becker muscular dystrophy and inclusion body myositis showed increased fiber diameter and improved walking distance, which grades B. The injectable 'Follistatin-344' peptide has no human trial and is Grade D. For human RCT data of any kind, CJC-1295 with DAC and ipamorelin lead — but those trials only proved GH and IGF-1 rise and never measured muscle. The honest headline: no peptide has Grade A human muscle-outcome evidence, and the best-supported real muscle growth comes from a gene therapy, not a bottle.
Is IGF-1 LR3 a safe way to add lean mass?
No. It has zero published human clinical trials for any indication. In animals it is more potent than native IGF-1 largely because it evades the binding proteins that normally sequester IGF-1, but that potency drives disproportionate visceral organ growth rather than balanced muscle. In the most rigorous recent animal study, growth-restricted fetal sheep, it failed to improve body weight and caused four fetal demises — all in LR3-treated animals — with roughly 42% glucose drops, and dose-escalation was halted for safety. Hypoglycemia is the dominant acute hazard because IGF-1-receptor signaling overlaps insulin's, and chronically high IGF-1 is associated with increased cancer risk in large human epidemiology. It is the highest-risk, weakest-evidence option in this review.
Does raising growth hormone with these peptides reliably build muscle?
Not as demonstrated. The longest human RCT of a growth-hormone secretagogue, the oral ghrelin mimetic MK-677, ran two years in older adults: it raised GH and IGF-1 to young-adult levels and increased fat-free mass, but produced no gain in strength or function and worsened insulin sensitivity and fasting glucose. That result is the template for the whole field — the number on the body-composition scan can change while the thing you actually care about, functional strength, does not. No GH-secretagogue peptide in this review, including CJC-1295 and ipamorelin, has a completed trial that measured muscle, lean mass or strength as an outcome. Biomarker movement is not the same as performance.
Are these peptides legal, and will they cause a failed drug test?
None is FDA-approved for building muscle; most are sold as unapproved research chemicals, and CJC-1295 was rejected by the FDA's Pharmacy Compounding Advisory Committee for compounding eligibility in December 2024 while ipamorelin is not on the permitted bulks list. For any tested athlete the situation is unambiguous: every peptide here is prohibited by WADA at all times. GH-releasing factors such as CJC-1295 fall under S2.2.4, IGF-1 analogs and MGF under S2, and follistatin and myostatin-pathway agents under S4.3, with AAV follistatin also captured under M3 gene doping. A 'research-grade' or 'supplement' label gives no exemption, several agents are detectable for weeks, and strict liability means a sanction is the most probable outcome for a competitive athlete.
What about injectable MGF or PEG-MGF — doesn't it replicate the post-workout repair signal?
The human data are expression studies, not intervention trials. MGF messenger RNA rises after high-resistance exercise, but only in young muscle — a controlled study found the increase in men aged 25 to 36 but not in men aged 70 to 82, suggesting age-related desensitization. In cell culture the MGF E-peptide extended the proliferative lifespan of muscle progenitor cells from young but not old donors. Crucially, no human interventional trial of injected MGF or PEG-MGF exists, so the injectable product is Grade D. Mechanistic work is more troubling still: the E-peptide's effects are not mediated by the IGF-1 receptor, and one review argues MGF may act largely as an intracellular peptide, which casts doubt on how an injected extracellular peptide would even work.
Is the popular CJC-1295 plus ipamorelin stack proven for body recomposition?
No. The pathway logic is real — combining a GHRH-receptor agonist like CJC-1295 with a ghrelin agonist like ipamorelin produces interactive, supra-additive growth-hormone output at the human hormonal level. But there are no published human randomized trials of the specific CJC-1295-plus-ipamorelin combination, and certainly none measuring muscle, lean mass or strength. The individual components only have biomarker RCTs, and ipamorelin's single efficacy RCT, in postoperative ileus, failed its primary endpoint and led to program discontinuation. So every body-recomposition claim for the stack is Grade C or D — extrapolated from hormone kinetics and recombinant-GH literature, not demonstrated for the combination in a controlled human trial.